Banerjee Kaushik, Basu Soumya, Das Satyajit, Sinha Abhinaba, Biswas Manas Kumar, Choudhuri Soumitra Kumar
a Department of In Vitro Carcinogenesis and Cellular Chemotherapy , Chittaranjan National Cancer Institute , Kolkata , West Bengal , India ;
b Department of Chemistry , Ramakrishna Mission Residential College , Kolkata , West Bengal , India.
Free Radic Res. 2016;50(4):426-46. doi: 10.3109/10715762.2015.1136062. Epub 2016 Feb 12.
Multidrug resistance (MDR) in cancer represents a variety of strategies employed by tumor cells to evade the beneficial cytotoxic effects of structurally different anticancer drugs and thus confers impediments to the successful treatment of cancers. Efflux of drugs by MDR protein-1, functional P-glycoprotein and elevated level of reduced glutathione confer resistance to cell death or apoptosis and thus provide a possible therapeutic target for overcoming MDR in cancer. Previously, we reported that a Schiff base ligand, potassium-N-(2-hydroxy 3-methoxy-benzaldehyde)-alaninate (PHMBA) overcomes MDR in both in vivo and in vitro by targeting intrinsic apoptotic/necrotic pathway through induction of reactive oxygen species (ROS). The present study describes the synthesis and spectroscopic characterization of a copper chelate of Schiff base, viz., copper (II)-N-(2-hydroxy-3-methoxy-benzaldehyde)-alaninate (CuPHMBA) and the underlying mechanism of cell death induced by CuPHMBA in vitro. CuPHMBA kills both the drug-resistant and sensitive cell types irrespective of their drug resistance phenotype. The cell death induced by CuPHMBA follows apoptotic pathway and moreover, the cell death is associated with intrinsic mitochondrial and extrinsic receptor-mediated pathways. Oxidative stress plays a pivotal role in the process as proved by the fact that antioxidant enzyme; polyethylene glycol conjugated-catalase completely blocked CuPHMBA-induced ROS generation and abrogated cell death. To summarize, the present work provides a compelling rationale for the future clinical use of CuPHMBA, a redox active copper chelate in the treatment of cancer patients, irrespective of their drug-resistance status.
癌症中的多药耐药性(MDR)代表肿瘤细胞采用的多种策略,以逃避结构不同的抗癌药物的有益细胞毒性作用,从而给癌症的成功治疗带来阻碍。MDR蛋白-1、功能性P-糖蛋白导致药物外排以及还原型谷胱甘肽水平升高,赋予细胞对死亡或凋亡的抗性,从而为克服癌症中的MDR提供了一个可能的治疗靶点。此前,我们报道了一种席夫碱配体,N-(2-羟基-3-甲氧基苯甲醛)-丙氨酸钾(PHMBA),通过诱导活性氧(ROS)靶向内在凋亡/坏死途径,在体内和体外均可克服MDR。本研究描述了席夫碱铜螯合物,即N-(2-羟基-3-甲氧基苯甲醛)-丙氨酸铜(II)(CuPHMBA)的合成及光谱表征,以及CuPHMBA在体外诱导细胞死亡的潜在机制。CuPHMBA能杀死耐药和敏感细胞类型,而不论其耐药表型如何。CuPHMBA诱导的细胞死亡遵循凋亡途径,此外,细胞死亡与内在线粒体途径和外在受体介导的途径有关。氧化应激在这一过程中起关键作用,这一事实证明抗氧化酶聚乙二醇共轭过氧化氢酶完全阻断了CuPHMBA诱导的ROS生成并消除了细胞死亡。总之,本研究为CuPHMBA(一种氧化还原活性铜螯合物)在未来临床治疗癌症患者中的应用提供了令人信服的理论依据,而不论其耐药状态如何。